Remus Pharmaceutical

Remus Pharmaceuticals approved the migration of its securities from NSE’s Emerge platform to the main boards of NSE and BSE, subject to shareholder, exchange and other regulatory approvals. The board also approved the incorporation of a subsidiary in the Dominican Republic to supply and distribute pharmaceutical products, with Remus to hold at least 51% of the entity. It appointed Ashutosh Valani, co-founder of Renee Cosmetics and former founder of Beardo and Villain, as a non-executive independent director for a first term of five years. The group’s international activity included a B2C launch in Bolivia and a cleared Peru audit enabling 60 product filings.

Powered by Tijori

Remus Pharmaceuticals appointed Ashutosh Naginbhai Valani as an additional non-executive independent director for a first five-year term. The board also approved migration of the company's securities from NSE Emerge to the NSE and BSE main boards, subject to shareholder, exchange and other regulatory approvals. It approved the incorporation of a Dominican Republic subsidiary to supply and distribute pharmaceutical products, with Remus set to subscribe in cash to more than 51% of its initial paid-up capital; the subscription amount was not specified. Valani is the co-founder and director of Renee Cosmetics and previously founded Beardo and Villain. Remus operated an asset-light pharmaceutical marketing and distribution business with a consolidated revenue run-rate of about ₹850 crore, while its US subsidiary Espree Global contributed roughly 70% of group revenue.

Powered by Tijori

June 23 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:

• APPOINTS BHAVIK SHAH AS CHIEF FINANCIAL OFFICER EFFECTIVE JULY 09, 2026

Source text: ID:nNSE353CY2

Further company coverage: REMP.NS

(([email protected];))

June 22 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:

• REMUS PHARMACEUTICALS - ANJALI SHAH RESIGNS AS CHIEF FINANCIAL OFFICER EFFECTIVE JULY 8, 2026

Source text: ID:nNSE30NzN4

Further company coverage: REMP.NS

(([email protected];))

Aug 29 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:

• RE-APPOINTS ARPIT SHAH AS MANAGING DIRECTOR

Source text: ID:nNSEbXnMqX

Further company coverage: REMP.NS

(([email protected];;))

June 20 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:

• INCORPORATES SUBSIDIARY FOR CLINICAL TRIAL MATERIAL MANAGEMENT

Source text: ID:nNSEbjVg2k

Further company coverage: REMP.NS

(([email protected];;))

Feb 7 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:

• ACQUIRING MEMBERSHIP INTEREST OF 56.67% IN ESPEE GLOBAL HOLDINGS

• APPROVED SETTING UP OF A BRANCH OFFICE IN DUBAI

• ESPEE DEAL FOR $ 2.7 MILLION

Source text for Eikon: ID:nNSE5csCmR

Further company coverage: REMP.NS

(([email protected];))

Oct 19 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:

• APPROVED TO SALE ENTIRE STAKE IT IN UNIT RATNATRIS PHARMACEUTICALS BY WAY OF SHARES SWAP

• DISPOSAL/SALE BY WAY OF SHARES SWAP

Source text for Eikon: ID:nNSE19SdWv

Further company coverage: REMP.NS

(([email protected];))

Sept 15 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:

• TO MAKE A STRATEGIC INVESTMENT IN ESPEE BIOPHARMA & FINECHEM LLC

• INVESTMENT BY ACQUIRING AND/OR SUBSCRIBING TO MEMBERSHIP INTEREST OF 51% OR MORE STAKE IN INVESTEE COMPANY

Source text for Eikon: ID:nNSE5CWGZ6

Further company coverage: REMP.NS

(([email protected];))

Aug 4 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:

• APPROVED IN PRINCIPLE TO INCORPORATE 2 SUBSIDIARIES AND 2 WHOLLY OWNED SUBSIDIARIES OUTSIDE INDIA

Source text for Eikon: ID:nNSE527SYr

Further company coverage: REMP.NS

(([email protected];;))